MECHELEN, Belgium I November 9, 2020 I Galapagos NV (Euronext & NASDAQ: GLPG) announces dosing of the first psoriasis patient in the Phase 1b trial with GLPG3667.
GLPG3667 is a proprietary compound with an undisclosed mechanism of action in development for inflammatory and autoimmune indications. Based on an initial clinical study in healthy volunteers, GLPG3667 has met the criteria to be further studied in patients.
This Phase 1b trial is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of GLPG3667. A daily oral administration of GLPG3667 at two different dose levels or a placebo will be investigated for 4 weeks in 30 patients with moderate to severe plaque psoriasis. The primary endpoint will be the change from baseline in Psoriasis Area Severity Index (PASI) score at 4 weeks. The first patient was dosed today. Recruitment will be based in Europe.
Pending successful completion of the Phase 1b study in psoriasis, we anticipate evaluating GLPG3667 in dose range finding Phase 2 studies in psoriatic arthritis and ulcerative colitis in the second half of 2021.
“We continue to press forward with several mechanisms of action in inflammation as part of our strategy to bring improved therapies to patients. We look forward to applying our extensive clinical experience in inflammation to this additional approach with GLPG3667. The study in psoriasis and the biomarker information collected should pave the way for trials in psoriatic arthritis and other indications,” said Dr. Piet Wigerinck, Chief Scientific Officer of Galapagos.
GLPG3667 is an investigational drug and not approved by any regulatory authority. Its efficacy and safety have not been established.
About our early inflammation pipeline
Galapagos continues to innovate in the inflammation space, with multiple, distinct mechanism of action approaches to bringing new therapy options to patients. GLPG3667 is an oral small molecule with undisclosed mechanism of action currently in Phase 1 trials.
For more information about our early clinical programs: www.glpg.com/other-programs
For information about the studies with GLPG3667 in psoriasis (NCT04594928): www.clinicaltrials.gov
About Galapagos
Galapagos NV discovers and develops small molecule medicines with novel modes of action, several of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises discovery through Phase 3 programs in inflammation, fibrosis and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.
SOURCE: Galapagos
Post Views: 366
MECHELEN, Belgium I November 9, 2020 I Galapagos NV (Euronext & NASDAQ: GLPG) announces dosing of the first psoriasis patient in the Phase 1b trial with GLPG3667.
GLPG3667 is a proprietary compound with an undisclosed mechanism of action in development for inflammatory and autoimmune indications. Based on an initial clinical study in healthy volunteers, GLPG3667 has met the criteria to be further studied in patients.
This Phase 1b trial is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of GLPG3667. A daily oral administration of GLPG3667 at two different dose levels or a placebo will be investigated for 4 weeks in 30 patients with moderate to severe plaque psoriasis. The primary endpoint will be the change from baseline in Psoriasis Area Severity Index (PASI) score at 4 weeks. The first patient was dosed today. Recruitment will be based in Europe.
Pending successful completion of the Phase 1b study in psoriasis, we anticipate evaluating GLPG3667 in dose range finding Phase 2 studies in psoriatic arthritis and ulcerative colitis in the second half of 2021.
“We continue to press forward with several mechanisms of action in inflammation as part of our strategy to bring improved therapies to patients. We look forward to applying our extensive clinical experience in inflammation to this additional approach with GLPG3667. The study in psoriasis and the biomarker information collected should pave the way for trials in psoriatic arthritis and other indications,” said Dr. Piet Wigerinck, Chief Scientific Officer of Galapagos.
GLPG3667 is an investigational drug and not approved by any regulatory authority. Its efficacy and safety have not been established.
About our early inflammation pipeline
Galapagos continues to innovate in the inflammation space, with multiple, distinct mechanism of action approaches to bringing new therapy options to patients. GLPG3667 is an oral small molecule with undisclosed mechanism of action currently in Phase 1 trials.
For more information about our early clinical programs: www.glpg.com/other-programs
For information about the studies with GLPG3667 in psoriasis (NCT04594928): www.clinicaltrials.gov
About Galapagos
Galapagos NV discovers and develops small molecule medicines with novel modes of action, several of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises discovery through Phase 3 programs in inflammation, fibrosis and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.
SOURCE: Galapagos
Post Views: 366
